Decoy chemokine neutraligands with anti-asthmatic activity

Dayana Abboud (Illkirch, France), Dayana Abboud, François Daubeuf, Quoc tuan Do, Valérie Utard, Pascal Villa, Jacques Haiech, Dominique Bonnet, Marcel Hibert, Philippe Bernard, Jean-Luc Galzi, Nelly Frossard

Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Session: Novel treatments for cough, asthma, COPD and bronchiectasis
Session type: Thematic Poster Session
Number: 3954
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Dayana Abboud (Illkirch, France), Dayana Abboud, François Daubeuf, Quoc tuan Do, Valérie Utard, Pascal Villa, Jacques Haiech, Dominique Bonnet, Marcel Hibert, Philippe Bernard, Jean-Luc Galzi, Nelly Frossard. Decoy chemokine neutraligands with anti-asthmatic activity. Eur Respir J 2015; 46: Suppl. 59, 3954

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines
Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Year: 2014

LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013


Differential effects of simvastatin and dexamethasone on TLR3-induced anti-viral cytokines in asthmatic epithelium
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013

Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists
Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Year: 2014


Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016



A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

Regulation of inflammatory cytokines in human immunocompetent cells by propranolol in vitro
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016

Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists
Source: Annual Congress 2013 –The pulmonary epithelium: recent developments
Year: 2013


Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016

The electrophilic 17-oxo-docosahexaenoic acid (17-oxo-DHA) enhances the anti-inflammatory potency of fluticasone propionate
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015

The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

Anti-inflammatory effects of resveratrol analogues in cellular models of airway inflammation
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015

Adiponectin acts as an anti-inflammatory cytokine on human lung macrophages
Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection
Year: 2013


An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013

Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

The anti-inflammatory effects of eucalyptol in a mouse model of LPS-induced pulmonary inflammation are mediated by TRPM8
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016

AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014

In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014